President Lee Donghoon of SK Biopharmaceuticals: "AI and Open Innovation Are Key to New Drug Development" [BIO USA]
"If we approach the new drug pipeline solely through organic (in-house) development, it takes 10 years. To shorten this timeline, we will focus on two pillars: open innovation via external collaboration and the adoption of artificial intelligence (AI)."
Lee Donghoon, President of SK Biopharmaceuticals, held a press conference at the SK Biopharmaceuticals booth during the opening of the world's largest bio and pharmaceutical expo, "2026 Bio International Convention (BIO USA)," on the 22nd (local time) in San Diego, USA. Photo by the joint press corps
View original imageLee Donghoon, President of SK Biopharmaceuticals, stated this during a press conference held at the '2026 BIO International Convention (BIO USA)' in San Diego, USA, on June 22 (local time). He remarked, "It took 30 years to directly develop and commercialize the epilepsy drug Xcopri," adding, "Based on this experience and the resulting cash flow, our current challenge is to secure a new drug pipeline that we can lead through to commercialization."
As the first outcome of this strategy, SK Biopharmaceuticals has signed a joint research and development agreement with AI-based drug discovery company Insilico Medicine to discover neuroimmune candidates in the central nervous system (CNS) area. The total contract value, including milestones, is up to $2.57 billion, with an upfront payment of $4.5 million. This agreement is significant as it marks the first AI-based drug discovery (AIDD) initiative realized through the Open Innovation Center (OIC) established by SK Biopharmaceuticals. Leveraging its expertise in epilepsy and CNS fields built through cenobamate, the company plans to expand its research scope into the new therapeutic area of neuroimmunity, thereby pursuing both qualitative and quantitative diversification of its CNS portfolio.
This agreement is not a simple contract research arrangement; rather, both parties will jointly lead the entire process, from target selection to stage-gate validation. By holding leadership from the initial discovery phase, SK Biopharmaceuticals aims to maximize the value of its drug assets. All intellectual property (IP) will be secured by SK Biopharmaceuticals, which will also be solely responsible for clinical development, manufacturing, and commercialization. SK Biopharmaceuticals plans to utilize Insilico's AI drug development platform, Pharma.AI, in the early discovery and preclinical phases to shorten the candidate identification period by nearly 50% compared to conventional research methods and to significantly reduce early discovery costs.
Hwang Seongwan, Chief Technology Officer (CTO) and Head of New Drug Research at SK Biopharmaceuticals, said, "The industry average for identifying non-clinical candidates is 4.5 years, but through this collaboration, we have set our goal at 2 years." He emphasized, "Securing an additional two years of exclusive sales period for a new drug through more than 50% reduction in development time is extremely meaningful in terms of market positioning."
This collaboration will not be limited to short-term results. All molecular design data, AI prediction and validation data, and structure-activity relationship (SAR) data produced during joint research will be accumulated by SK Biopharmaceuticals, enhancing its in-house AI capabilities. In the short term, this will enable rapid generation of new drug candidates; in the mid-to-long term, it will provide data assets to further advance the company's AI- and digital transformation (DT)-based drug design capabilities.
SK Biopharmaceuticals plans to use this collaboration as the starting point for establishing its 'Extended R&D Lab' model, which will organically leverage external technologies as part of its own research infrastructure. Shortening development timelines translates directly into a faster pipeline expansion. President Lee said, "Xcopri currently holds the number one market share in the CNS field and is expected to maintain this position for the next five to ten years. Based on this cash flow, we will launch a second product and expand beyond CNS into new modalities."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Additionally, President Lee unveiled the 'East-West Bridge' initiative to support the commercialization of Asian biotech companies in the US. He noted, "Just looking at the Korea Pavilion at BIO USA, it is clear that domestic public institutions, universities, and startups have strong capabilities," but also pointed out, "The problem is that there is no link to connect them all together." To address this, SK Biopharmaceuticals has established 'LYNX,' a global incubation hub in its New Jersey office in partnership with KOTRA, the Korea Health Industry Development Institute, and others. President Lee stated, "Over the next five to ten years, we aim to establish a win-win model by discovering outstanding early-stage assets from Asia and connecting them with direct sales infrastructure in the US."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.